Yes, mFOLFOX6 is administered every 14 days (2-week intervals)
mFOLFOX6 chemotherapy is standardly given on a 14-day cycle, with treatment repeated every 2 weeks. This is the established and validated schedule across all major guidelines and clinical trials.
Standard mFOLFOX6 Dosing Schedule
- Oxaliplatin: 85 mg/m² IV over 2 hours, day 1
- Leucovorin: 400 mg/m² IV over 2 hours, day 1
- 5-FU bolus: 400 mg/m² IV bolus on day 1
- 5-FU continuous infusion: 2,400 mg/m² over 46-48 hours (1,200 mg/m²/day × 2 days)
- Cycle repeats every 2 weeks (14 days)
This 14-day interval is consistent across:
When Combined with Biologics
The 14-day schedule remains unchanged when adding targeted agents 1, 2:
- Bevacizumab: 5 mg/kg IV day 1, every 2 weeks with mFOLFOX6
- Panitumumab: 6 mg/kg IV day 1, every 2 weeks with mFOLFOX6
Clinical Evidence Supporting the 14-Day Schedule
Multiple landmark trials established this schedule 1:
- NO16966 trial: Validated mFOLFOX6 every 2 weeks in metastatic colorectal cancer
- PEAK trial: Confirmed the 2-week schedule with panitumumab
- Multiple phase III studies: Consistently used 14-day cycles
Important Distinction from FOLFOX4
Do not confuse mFOLFOX6 with FOLFOX4, which also uses a 2-week cycle but has different 5-FU dosing (600 mg/m² over 22 hours on days 1 and 2, rather than the 46-48 hour continuous infusion) 3.
Practical Considerations
- The 14-day interval allows adequate recovery from myelosuppression while maintaining dose intensity
- Treatment continues every 2 weeks until disease progression, unacceptable toxicity, or completion of planned cycles (typically 12 cycles in adjuvant setting)
- Dose modifications for toxicity do not change the 14-day schedule—only the drug doses are adjusted
There is no alternative standard schedule for mFOLFOX6; the every-2-week administration is the only validated regimen.